STOCKHOLM, Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease, CTAD, congress, held in Madrid, Spain, and virtually, October 29 to November 1. Three-year data show that lecanemab continues to give increased patient benefit for patients with early Alzheimer's disease, expanding approximately 1 point on CDR-SB compared to the ADNI[1]-population, with maintained safety profile.
In addition, data show that 46% of patients who had low levels of brain amyloid at the start of treatment have improved or maintained cognition and function after three years of treatment. Highlights from the presentations at CTAD included: Benefits of continued treatment with lecanemab for people with early Alzheimer's disease Results from the open-label long-term extension study (OLE) following the core study of the lecanemab phase 3 Clarity AD study presented at AAIC in July, showed that the mean change from baseline in CDR-SB (global cognitive and functional scale) in the lecanemab treated group was -0.45 at 18 months compared to the placebo group.
This had expanded to -0.95 compared to the ADNI-population at 36 months. The data also showed a 30% reduction in the risk of progressing to the next disease stage.
Furthermore, the tau PET substudy of Clarity AD showed that with three years of continuous treatment with lecanemab, 59% of patients with no or low t.
